Literature DB >> 11874717

Expression and action of the growth hormone releasing peptide ghrelin and its receptor in prostate cancer cell lines.

P L Jeffery1, A C Herington, L K Chopin.   

Abstract

This study has examined the expression of two new facets of the growth hormone axis, the growth hormone secretagogue receptor (GHS-R) and its recently identified putative natural ligand ghrelin, in prostate cancer cells. GHS-R 1a and 1b isoforms and ghrelin mRNA expression were detected by RT-PCR in the ALVA-41, LNCaP, DU145 and PC3 prostate cancer cell lines. A normal prostate cDNA library expressed GHS-R1a, but not the 1b isoform or ghrelin. Immunohistochemical staining for the GHS-R 1a isoform and ghrelin was positive in the four cell lines studied. PC3 cells showed increased cell proliferation in vitro in response to ghrelin to levels 33% above untreated controls, implying a potential tumour-promoting role for ghrelin in this tissue. This study is the first to demonstrate the co-expression of the GHS-R and ghrelin in prostate cancer cells. It is also the first study to provide evidence that a previously unrecognised autocrine/paracrine pathway involving ghrelin, that is capable of stimulating growth, exists in prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11874717     DOI: 10.1677/joe.0.172r007

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  35 in total

1.  Limited short-term effects on human prostate cancer xenograft growth and epidermal growth factor receptor gene expression by the ghrelin receptor antagonist [D-Lys3]-GHRP-6.

Authors:  Michelle L Maugham; Inge Seim; Patrick B Thomas; Gabrielle J Crisp; Esha T Shah; Adrian C Herington; Laura S Gregory; Colleen C Nelson; Penny L Jeffery; Lisa K Chopin
Journal:  Endocrine       Date:  2018-11-02       Impact factor: 3.633

2.  Ghrelin and cortistatin in lung cancer: expression of peptides and related receptors in human primary tumors and in vitro effect on the H345 small cell carcinoma cell line.

Authors:  P Cassoni; E Allia; T Marrocco; C Ghè; E Ghigo; G Muccioli; M Papotti
Journal:  J Endocrinol Invest       Date:  2006-10       Impact factor: 4.256

3.  Ghrelin antagonized 1-methyl-4-phenylpyridinium (MPP(+))-induced apoptosis in MES23.5 cells.

Authors:  Juanjuan Dong; Ning Song; Junxia Xie; Hong Jiang
Journal:  J Mol Neurosci       Date:  2008-12-04       Impact factor: 3.444

4.  2018 CUA Abstracts.

Authors: 
Journal:  Can Urol Assoc J       Date:  2018-06       Impact factor: 1.862

Review 5.  T-type Ca2+ channels and the urinary and male genital tracts.

Authors:  C H Fry; R I Jabr
Journal:  Pflugers Arch       Date:  2014-01-25       Impact factor: 3.657

6.  Ghrelin localization in rat and human thyroid and parathyroid glands and tumours.

Authors:  Kawtar Raghay; Tomás García-Caballero; Rubén Nogueiras; Gérard Morel; Andrés Beiras; Carlos Diéguez; Rosalía Gallego
Journal:  Histochem Cell Biol       Date:  2005-09-27       Impact factor: 4.304

7.  Serum ghrelin is inversely associated with risk of subsequent oesophageal squamous cell carcinoma.

Authors:  Gwen Murphy; Farin Kamangar; Demetrius Albanes; Frank Z Stanczyk; Stephanie J Weinstein; Philip R Taylor; Jarmo Virtamo; Christian C Abnet; Sanford M Dawsey; Neal D Freedman
Journal:  Gut       Date:  2011-12-16       Impact factor: 23.059

8.  Expression and in vitro functions of the ghrelin axis in endometrial cancer.

Authors:  Jenny N T Fung; Inge Seim; Dengfeng Wang; Andreas Obermair; Lisa K Chopin; Chen Chen
Journal:  Horm Cancer       Date:  2010-10       Impact factor: 3.869

9.  Ghrelin stimulates proliferation of human osteoblastic TE85 cells via NO/cGMP signaling pathway.

Authors:  Deng-Hu Wang; Yun-Sheng Hu; Jun-Jie Du; Yun-Yu Hu; Wei-De Zhong; Wei-Jun Qin
Journal:  Endocrine       Date:  2008-10-25       Impact factor: 3.633

10.  Distribution of obestatin and ghrelin in human tissues: immunoreactive cells in the gastrointestinal tract, pancreas, and mammary glands.

Authors:  Malin Grönberg; Apostolos V Tsolakis; Linda Magnusson; Eva T Janson; Jan Saras
Journal:  J Histochem Cytochem       Date:  2008-05-12       Impact factor: 2.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.